C
Cyrille Hulin
Researcher at University of Bordeaux
Publications - 244
Citations - 17506
Cyrille Hulin is an academic researcher from University of Bordeaux. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 51, co-authored 197 publications receiving 14696 citations.
Papers
More filters
Journal ArticleDOI
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal,Valérie Lauwers-Cances,Gerald Marit,Denis Caillot,Philippe Moreau,Thierry Facon,Anne-Marie Stoppa,Cyrille Hulin,Lofti Benboubker,Laurent Garderet,Olivier Decaux,Serge Leyvraz,Marie-Christiane Vekemans,Laurent Voillat,Mauricette Michallet,Brigitte Pegourie,Charles Dumontet,Murielle Roussel,Xavier Leleu,Claire Mathiot,Catherine Payen,Hervé Avet-Loiseau,Jean-Luc Harousseau +22 more
TL;DR: Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma.
Journal ArticleDOI
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Michel Attal,Jean-Luc Harousseau,Thierry Facon,François Guilhot,Chantal Doyen,Jean-Gabriel Fuzibet,Mathieu Monconduit,Cyrille Hulin,Denis Caillot,Reda Bouabdallah,Laurent Voillat,Jean-Jacques Sotto,Bernard Grosbois,Régis Bataille +13 more
TL;DR: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Journal ArticleDOI
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau,Michel Attal,Philippe Moreau,Catherine Charbonnel,Frédéric Garban,Cyrille Hulin,Serge Leyvraz,Mauricette Michallet,Ibrahim Yakoub-Agha,Laurent Garderet,Gerald Marit,Lucienne Michaux,Laurent Voillat,Marc Renaud,Bernard Grosbois,Gaelle Guillerm,Lotfi Benboubker,Mathieu Monconduit,Catherine Thieblemont,Philippe Casassus,Denis Caillot,Anne-Marie Stoppa,Jean-Jacques Sotto,Marc Wetterwald,Charles Dumontet,Jean-Gabriel Fuzibet,Isabelle Azais,Véronique Dorvaux,Marc Zandecki,Régis Bataille,Stephane Minvielle,Jean-Luc Harousseau,Thierry Facon,Claire Mathiot +33 more
TL;DR: In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival and have implications for the design of risk-adapted treatment strategies.
Journal ArticleDOI
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Thierry Facon,Jean Yves Mary,Cyrille Hulin,Lotfi Benboubker,Michel Attal,Brigitte Pegourie,Marc Renaud,Jean Luc Harousseau,Gaelle Guillerm,Carine Chaleteix,Mamoun Dib,Laurent Voillat,Hervé Maisonneuve,Jacques Troncy,Véronique Dorvaux,Mathieu Monconduit,Claude Martin,Philippe Casassus,Jérôme Jaubert,H. Jardel,Chantal Doyen,Brigitte Kolb,Bruno Anglaret,Bernard Grosbois,Ibrahim Yakoub-Agha,Claire Mathiot,Hervé Avet-Loiseau +26 more
TL;DR: The results of this trial provide strong evidence to indicate that the use of thalidomide in combination with melphalan and prednisone should, at present, be the reference treatment for previously untreated elderly patients with multiple myeloma.
Journal ArticleDOI
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal,Valérie Lauwers-Cances,Cyrille Hulin,Xavier Leleu,Denis Caillot,Martine Escoffre,Bertrand Arnulf,Margaret Macro,Karim Belhadj,Laurent Garderet,Murielle Roussel,Catherine Payen,Claire Mathiot,Jean Paul Fermand,Nathalie Meuleman,Sandrine Rollet,Michelle E. Maglio,Andrea A. Zeytoonjian,Edie Weller,Nikhil C. Munshi,Kenneth C. Anderson,Paul G. Richardson,Thierry Facon,Hervé Avet-Loiseau,Jean-Luc Harousseau,Philippe Moreau +25 more
TL;DR: Among adults with multiple myeloma, RVD therapy plus transplantation was associated with significantly longer progression‐free survival than RVD Therapy alone, but overall survival did not differ significantly between the two approaches.